lupartumab amadotin (BAY1129980) / Bayer - LARVOL DELTA

Targeting of a cancer-associated LYPD3 glycoform for tumor therapy (SITC 2022) - "Notably, GT-002 elicits markedly reduced binding to normal human tissues compared to anti-LYPD3 polyclonal control antibodies or Lupartumab, an anti-LYPD3 antibody previously in clinical development as ADC (BAY1129980). By using this approach, we were able to develop an anti-LYPD3 antibody that stains cancer tissue of various indications while showing drastically reduced off-tumor binding towards healthy LYPD3-positive tissues. We believe that this highly specific antibody is exceptionally suitable for potent therapies like ADCs, radio-conjugates and CARs."

Colorectal Cancer • Esophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • LYPD3

Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - P1; N=69; Terminated; Sponsor: Bayer; Completed ➔ Terminated

Clinical • Trial termination

Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (clinicaltrials.gov) - P1; N=70; Completed; Sponsor: Bayer; Terminated ➔ Completed

Clinical • Trial completion